DNA damage is significant in endothelial cells (EC), particularly in anticancer chemotherapy. Here, we explored whether and how aphidicolin, a DNA-damaging chemical with a promising anticancer activity, alters NO production in bovine aortic endothelial cells (BAEC). In addition to increasing eNOS-Ser phosphorylation, aphidicolin decreased eNOS-Ser phosphorylation with a concomitant increase in NO production in a time-dependent manner. The amino acid sequence around the eNOS-Ser residue was identified as the substrate site of the regulatory subunit B56δ of protein phosphatase 2A (PP2A). As expected, okadaic acid, a specific PP2A inhibitor, reversed aphidicolin-induced eNOS-Ser dephosphorylation in a dose-dependent manner. Aphidicolin also increased B56δ-Ser phosphorylation, although expression of neither the catalytic subunit Cα (PP2A Cα) nor B56δ was altered. Ectopic expression of dominant negative (dn)-B56δ reversed all of the observed effects of aphidicolin with respect to phosphorylation of eNOS-Ser and B56δ-Ser. Lastly, aphidicolin-stimulated NO production was also partially attenuated by ectopic expression of dn-B56δ. Taken together, our results are the first to demonstrate that aphidicolin decreases phosphorylation of eNOS-Ser, at least in part by activating PP2A B56δ, resulting in NO release in BAEC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.niox.2015.08.001 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!